NEW YORK (GenomeWeb News) – Foundation Medicine's supply, service, and support agreement with Illumina inked in July is for five years and approximately $6.1 million, the Cambridge, Mass.-based firm said in an amended Form S-1 filed this week. The company originally disclosed the deal with Illumina in its Form S-1 filed in July in preparation of its initial public offering, but did not reveal the terms. Foundation plans to offer up to $86.3 million in its IPO.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.